首页> 美国卫生研究院文献>World Journal of Gastroenterology >Effect of Fuzheng Yiliu decoction combined with chemotherapy on patients with intermediate and late stage gastrointestinal cancer
【2h】

Effect of Fuzheng Yiliu decoction combined with chemotherapy on patients with intermediate and late stage gastrointestinal cancer

机译:扶正抑瘤汤联合化疗对中晚期胃肠道肿瘤的治疗作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIM: To investigate the therapeutic effects of Fuzheng Yiliu (strengthening the body resistance to inhibit tumor) decoction combined with chemotherapy on the patients with intermediate and late stage gastrointestinal cancer.METHODS: Sixty patients were randomly divided into treatment group (chemotherapy combined with Fuzheng Yiliu decoction) and control group (chemotherapy alone). Four indexes, including the tumor recent remission rate (RR), the change of main symptoms, the toxic and side effects caused by chemotherapy and the change of performance status, were observed in the patients. Peripheral blood contents of CD3+, CD4+, CD8+ cells, CD4+/CD8+ and soluble interleukin-2 receptor (sIL-2R) were tested before and after treatment and the values were compared with those of healthy peoples.RESULTS: The improving rate of main symptoms (69.6%) and performance status (56.7%) were significantly higher in the treatment group than in the control group (34.8%, 26.7%, P<0.05). The occurrence rates of grade II toxic and side-effects on both bone marrow (13.3%) and digestive tract (30%) were lower in the treatment group compared to the control group (36.7%, 63.3%, P<0.05). Before treatment, the proportion of CD3+, CD4+ and CD4+/CD8+ decreased and the proportion of CD8+ and sIL-2R raised markedly both in the control group and treatment group as compared to the healthy people. After treatment, that increased of CD3+, CD4+, CD4+/CD8+ increased (62.25±10.01% vs 68.31±9.72%, 36.83±10.44% vs 42.6±9.62%, 1.24±0.65 vs 1.66±0.85, P<0.05) and the values of CD8+ and sIL-2R decreased obviously (33.06±7.69% vs 29.24±6.25%, 588.23±216.86 U/mL vs 475.87±211.36 U/mL, P<0.05) in the treatment group, whereas these values were opposite in the control group (64.22±6.91% vs 60.63±5.75%, 35.62±7.49% vs 31.53±5.53%, 32.95±8.28% vs 37.14±7.48%, 1.17±0.43 vs 0.94±0.43, 573.63±214.32 U/mL vs 692.17±221.33 U/mL, P<0.05).CONCLUSION: Fuzheng Yiliu decoction can enhance therapeutic effects of chemotherapy on malignant gastrointestinal tumor, and also reduce the toxic and side effects on bone marrow and digestive tract, thereby improving the quality of life and cellular immunity in patients with malignant gastrointestinal tumor.
机译:目的:探讨扶正抑瘤汤联合化疗对中晚期胃肠道癌的治疗效果。方法:将60例患者随机分为治疗组(化学疗法联合扶正抑瘤)。汤)和对照组(仅化学疗法)。观察患者的肿瘤近期缓解率(RR),主要症状的变化,化疗引起的毒性和副作用以及行为状态的变化这四个指标。 CD3 + ,CD4 + ,CD8 + 细胞,CD4 + / CD8 + 和可溶性白细胞介素2受体(sIL-2R)在治疗前后进行了检测,并与健康人进行了比较。结果:主要症状改善率(69.6%)和运动状态改善(56.7%) )在治疗组中显着高于对照组(34.8%,26.7%,P <0.05)。与对照组(36.7%,63.3%,P <0.05)相比,治疗组在骨髓(13.3%)和消化道(30%)上的II级毒性和副作用的发生率均较低。治疗前,CD3 + ,CD4 + 和CD4 + / CD8 + 的比例降低,与健康人相比,对照组和治疗组的CD8 + 和sIL-2R均明显升高。治疗后,CD3 + ,CD4 + ,CD4 + / CD8 + 的增加(62.25±10.01) %vs 68.31±9.72%,36.83±10.44%vs 42.6±9.62%,1.24±0.65 vs 1.66±0.85,P <0.05),CD8 + 和sIL-2R值明显降低(33.06治疗组为±7.69%vs.29.24±6.25%,588.23±216.86 U / mL vs 475.87±211.36 U / mL,P <0.05),而对照组则相反(64.22±6.9​​1%vs 60.63±5.75) %,35.62±7.49%vs. 31.53±5.53%,32.95±8.28%vs 37.14±7.48%,1.17±0.43 vs 0.94±0.43,573.63±214.32 U / mL vs 692.17±221.33 U / mL,P <0.05)。 :扶正一流汤可增强化疗对恶性胃肠道肿瘤的治疗作用,并减少对骨髓和消化道的毒性和副作用,从而改善恶性胃肠道肿瘤患者的生活质量和细胞免疫力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号